Research Paper on:
Quitting Smoking by Using Zyban

Unformatted Sample Text from the Research Paper:
therapies, such as the nicotine patch, have been considered the first line of therapy in smoking cessation. Studies involving Zyban however, a slow-release drug in tablet form and not nicotine-based,  have shown that Zyban has been twice as effective at smoking cessation in both short-term and long-term abstinence rates. Zyban is also considered one of the least expensive therapies available  in addition to its providing fewer withdrawal side effects. Because of these recent successful trials on Zyban, health care professionals believe that it should be considered as the first line  therapy in smoking cessation and it has now been included in the coverage of several health care plans. In 1999, a study published  in the New England Journal of Medicine reported that the anti-depressant Zyban (bupropion) was nearly twice as effective as the nicotine patch in helping smokers and quit and maintain cessation  for up to one year. Since that time, global health agencies have recommended Zyban as one the leading health aids available to patients who want to stop smoking (Doctors Guide).  Zyban, which is not nicotine based was tested on over 900 smokers in its sustained-release tablet form. The study in 1999 not only tested the effectiveness of Zyban but  also studied its effects in relation and combination with nicotine replacement therapy (NPT). The study was done as a follow-up trial after a similar study was performed in 1997 which  had showed the effectiveness of Zyban in comparison with a placebo group. The subsequent study was performed to test the routine application of the nicotine patch as the first line  intervention for patients who want to quit smoking (Doctors Guide). Typical withdrawal symptoms for patients who quit smoking are cravings for cigarettes, restlessness, increased appetite, depression, anxiety, irritability and disrupted